TheraSpheres Treatment for Unresectable Hepatocarcinoma and Portal Vein Thrombosis

Completed · Not applicable

Conditions studied: Liver Cancer, Portal Vein Thrombosis

In brief

Therasphere will be administered via catheter through the Hepatic Artery to treat patients with Hepatocellular Carcinoma and Portal vein Thrombosis.

Key facts

Study ID

NCT01556282

Run by

Emory University

People needed

35

Starts

2009-03-01

Expected to finish

2014-01-01

Last updated by the study team

2014-05-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 yrs of age or older
• Diagnosis of Hepatocellular Carcinoma
• Portal Vein Thrombosis
• ECOG performance < 2
• >4 weeks since prior radiation, surgery or chemotherapy.
• Life expectancy > 3 months
• Able to provide written informed consent process in accordance with institutional review boards guidelines.

You may not qualify if…

• Contraindications to angiography and selective visceral catheterization.
• Evidence of blood flow to the lung from the liver greater than 16.5 mCi
• Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop or mitigate such flow.
• Significant extrahepatic disease.
• Severe liver disfunction of pulmonary insufficiency.
• Active uncontrolled infection.
• Significant underlying medical or psychiatric illness.
• Pregnancy. Patients will be excluded if they have pre-existing diarrhea/illness, or if they have a co-morbid disease or condition that would preclude safe delivery of TheraSphere treatment and place the patient at undue risk.

Where it is running

• Emory University Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.